Treatment of late onset bacterial sepsis caused by vancomycin susceptible bacteria in neonates and infants aged under three months.
Welcome in NeoVanc
NeoVanc project aims at adapting an off-patent medicine to the specific need of paediatric populations: in specific to develop an optimal dosing and monitoring regimen for vancomycin use in preterm neonates and infants under 3 months of age in order to be able to register it for use in this age group with a PUMA.
This project has been funded with the support of the European Commission under the FP7 programme.
Reserved Access to the our services for our Partners.